Dong Dong1,2, Richard Huan Xu1,2, Eliza Lai-Yi Wong1,2, Chi-Tim Hung1,2, Da Feng3, Zhanchun Feng4, Eng-Kiong Yeoh1,2, Samuel Yeung-Shan Wong1. 1. The Jockey Club School of Public Health & Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. 2. Centre for Health Systems and Policy Research, The Chinese University of Hong Kong, Hong Kong SAR, China. 3. School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China. 4. School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Abstract
BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic is sweeping across the globe, there is an urgent need to develop effective vaccines as the most powerful strategy to end the pandemic. This study aimed to examine how factors related to vaccine characteristics, their social normative influence and convenience of vaccination can affect the public's preference for the uptake of the COVID-19 vaccine in China. METHODS: An online discrete choice experiment (DCE) survey was administered to a sample of China's general population. Participants were asked to make a series of hypothetical choices and estimate their preference for different attributes of the vaccine. A mixed logit regression model was used to analyse the DCE data. Willingness to pay for each attribute was also calculated. RESULTS: Data of 1236 participants who provided valid responses were included in the analysis. There was strong public preference for high effectiveness of the vaccine, followed by long protective duration, very few adverse events and being manufactured overseas. Price was the least important attribute affecting the public preference in selecting the COVID-19 vaccine. CONCLUSIONS: The strong public preferences detected in this study should be considered when developing COVID-19 vaccination programme in China. The results provide useful information for policymakers to identify the individual and social values for a good vaccination strategy. PATIENT OR PUBLIC CONTRIBUTION: The design of the experimental choices was fully based on interviews and focus group discussions participated by 26 Chinese people with diverse socio-economic backgrounds. Without their participation, the study would not be possible.
BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic is sweeping across the globe, there is an urgent need to develop effective vaccines as the most powerful strategy to end the pandemic. This study aimed to examine how factors related to vaccine characteristics, their social normative influence and convenience of vaccination can affect the public's preference for the uptake of the COVID-19 vaccine in China. METHODS: An online discrete choice experiment (DCE) survey was administered to a sample of China's general population. Participants were asked to make a series of hypothetical choices and estimate their preference for different attributes of the vaccine. A mixed logit regression model was used to analyse the DCE data. Willingness to pay for each attribute was also calculated. RESULTS: Data of 1236 participants who provided valid responses were included in the analysis. There was strong public preference for high effectiveness of the vaccine, followed by long protective duration, very few adverse events and being manufactured overseas. Price was the least important attribute affecting the public preference in selecting the COVID-19 vaccine. CONCLUSIONS: The strong public preferences detected in this study should be considered when developing COVID-19 vaccination programme in China. The results provide useful information for policymakers to identify the individual and social values for a good vaccination strategy. PATIENT OR PUBLIC CONTRIBUTION: The design of the experimental choices was fully based on interviews and focus group discussions participated by 26 Chinese people with diverse socio-economic backgrounds. Without their participation, the study would not be possible.
Authors: Esther W de Bekker-Grob; Jorien Veldwijk; Marcel Jonker; Bas Donkers; Jan Huisman; Sylvia Buis; Joffre Swait; Emily Lancsar; Cilia L M Witteman; Gouke Bonsel; Patrick Bindels Journal: Vaccine Date: 2018-02-06 Impact factor: 3.641
Authors: Jason M Nagata; Isabel Hernández-Ramos; Anand Sivasankara Kurup; Daniel Albrecht; Claudia Vivas-Torrealba; Carlos Franco-Paredes Journal: BMC Public Health Date: 2013-04-25 Impact factor: 3.295
Authors: Lydia W Y Fung; Jiaxi Zhao; Vincent K C Yan; Joseph E Blais; Jacky C H Chan; Silvia T H Li; Jessica J P Shami; Christine Kwan; Yue Wei; Carlos K H Wong; Xue Li; Celine S L Chui; Eric Y F Wan; Francisco T T Lai; Samson Tse; Benjamin J Cowling; Ian C K Wong; Esther W Chan Journal: JAMA Netw Open Date: 2022-05-02
Authors: Julio Jaramillo-Monge; Michael Obimpeh; Bernardo Vega; David Acurio; Annelies Boven; Veronique Verhoeven; Robert Colebunders Journal: Vaccines (Basel) Date: 2021-06-21